Meeting
2011 ASCO Annual Meeting
Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.
Authors
S. M. Falzarano
Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
S. M. Falzarano , C. Magi-Galluzzi , W. F. Novotny , T. Maddala , D. B. Cherbavaz , C. Millward , E. A. Klein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4541)
Abstract #
4541
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes.
First Author: Felix Yi-Chung Feng
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
First Author: Edwin Melencio Posadas